Unicycive Therapeutics annual operating margin
2022
2023
Unicycive Therapeutics Operating Margin Growth & History (UNCY)
Unicycive Therapeutics's operating margin was −3,077.63% for fiscal 2023.
View full Unicycive Therapeutics company overviewUnicycive Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −3,077.63% | −1179.42 pp |
| 2022 | 2022-12-31 | −1,898.21% | — |
Unicycive Therapeutics quarterly operating margin
Q3.22
Q1.23
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2023 | 2023-03-31 | −622.52% | — |
| Q3 2022 | 2022-09-30 | −584.02% | — |
Unicycive Therapeutics operating margin trends
Between the periods ended 2022-12-31 and 2023-12-31, Unicycive Therapeutics's operating margin decreased from −1,898.21% to −3,077.63%, a change of −1179.42 percentage points. The latest reported quarter, Q1 2023, shows −622.52%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Unicycive Therapeutics source filings ↗Community posts
Unicycive resubmits kidney-drug application with new manufacturer data
Unicycive ($UNCY) resubmitted its US application for oxylanthanum carbonate, an investigational oral phosphate binder for dialysis patients with chronic kidney disease. The package includes manufacturing and quality data from a new third-pa ...
